Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE8A | O60658 | 1/20 | 0.35 |
| ▸ | PDE1A | P54750 | 1/20 | 0.32 |
| ▸ | PDE1B | Q01064 | 1/20 | 0.32 |
| ▸ | PDE1C | Q14123 | 1/20 | 0.32 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.31 |
| ▸ | DHFR | P00374 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1591003 | 0.73 | FLT3 (0.38) | — | |
| SCHEMBL4444396 | 0.71 | MAPK1 (0.38) | PIK3CA | |
| SCHEMBL2949862 | 0.62 | ADORA2A (0.51) | — | |
| SCHEMBL5392972 | 0.60 | PIK3CA (0.35) | PIK3CA | |
| SCHEMBL31704969 | 0.60 | PDE1A (0.36) | PDE1APDE1BPDE1CPIK3CA | |
| SCHEMBL1512058 | 0.59 | DHFR (0.35) | DHFR | |
| SCHEMBL5808473 | 0.58 | TNK2 (0.39) | PDE8APDE1BPIK3CADHFR | |
| SCHEMBL28344176 | 0.57 | ALDH1A1 (0.46) | PIK3CA | |
| Hydrochloric Acid SCHEMBL5626685 | 0.57 | AHCY (0.48) | PIK3CA | |
| SCHEMBL1512134 | 0.57 | DHFR (0.46) | PIK3CADHFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100056494-A1 | PURINE COMPOUNDS AND COMPOSITIONS AS KINASE INHIBITORS FOR THE TREATMENT OF PLASMODIUM RELATED DISEASES | IRM LLC (BM) | 2010-03-04 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100056494-A1 | PURINE COMPOUNDS AND COMPOSITIONS AS KINASE INHIBITORS FOR THE TREATMENT OF PLASMODIUM RELATED DISEASES | ADK, PNP, DCK | PDE8A 632/4885PDE1A 1568/4885PDE1B 1457/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.